Last reviewed · How we verify
Imiquimod 5% cream with prior curettage
Imiquimod 5% cream with prior curettage is a TLR7 agonist / Immune response modifier Small molecule drug developed by Maastricht University Medical Center. It is currently in Phase 3 development for Basal cell carcinoma (superficial or nodular) following curettage, Actinic keratosis, Cutaneous squamous cell carcinoma in situ. Also known as: Aldara.
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local anti-tumor and anti-viral immunity.
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to enhance local anti-tumor and anti-viral immunity. Used for Basal cell carcinoma (superficial or nodular) following curettage, Actinic keratosis, Cutaneous squamous cell carcinoma in situ.
At a glance
| Generic name | Imiquimod 5% cream with prior curettage |
|---|---|
| Also known as | Aldara |
| Sponsor | Maastricht University Medical Center |
| Drug class | TLR7 agonist / Immune response modifier |
| Target | TLR7 (Toll-like receptor 7) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Dermatology |
| Phase | Phase 3 |
Mechanism of action
Imiquimod binds to TLR7 on immune cells, triggering production of interferon-alpha and other cytokines that activate dendritic cells and T cells. When applied topically after curettage (mechanical removal of lesion), it promotes local immune-mediated destruction of remaining tumor cells. This combination approach leverages both mechanical debulking and immunological clearance.
Approved indications
- Basal cell carcinoma (superficial or nodular) following curettage
- Actinic keratosis
- Cutaneous squamous cell carcinoma in situ
Common side effects
- Local skin irritation / erythema
- Pruritus
- Erosion / ulceration
- Scabbing / crusting
- Systemic flu-like symptoms
- Lymphadenopathy
Key clinical trials
- Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imiquimod 5% cream with prior curettage CI brief — competitive landscape report
- Imiquimod 5% cream with prior curettage updates RSS · CI watch RSS
- Maastricht University Medical Center portfolio CI
Frequently asked questions about Imiquimod 5% cream with prior curettage
What is Imiquimod 5% cream with prior curettage?
How does Imiquimod 5% cream with prior curettage work?
What is Imiquimod 5% cream with prior curettage used for?
Who makes Imiquimod 5% cream with prior curettage?
Is Imiquimod 5% cream with prior curettage also known as anything else?
What drug class is Imiquimod 5% cream with prior curettage in?
What development phase is Imiquimod 5% cream with prior curettage in?
What are the side effects of Imiquimod 5% cream with prior curettage?
What does Imiquimod 5% cream with prior curettage target?
Related
- Drug class: All TLR7 agonist / Immune response modifier drugs
- Target: All drugs targeting TLR7 (Toll-like receptor 7)
- Manufacturer: Maastricht University Medical Center — full pipeline
- Therapeutic area: All drugs in Oncology / Dermatology
- Indication: Drugs for Basal cell carcinoma (superficial or nodular) following curettage
- Indication: Drugs for Actinic keratosis
- Indication: Drugs for Cutaneous squamous cell carcinoma in situ
- Also known as: Aldara
- Compare: Imiquimod 5% cream with prior curettage vs similar drugs
- Pricing: Imiquimod 5% cream with prior curettage cost, discount & access